Croissy-Beaubourg, January 8, 2020, 5.45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2020.
Events | Dates* |
2019 Full-Year Annual Revenue | Tuesday February 4, 2020 |
2019 Full-Year Results | Wednesday March 18, 2020 |
Annual General Meeting | Thursday May 14, 2020 |
2020 First-Half Revenue | Tuesday July 21, 2020 |
2020 First-Half Results | Monday September 21, 2020 |
(*) Subject to modifications. Press releases will be published after market close.
Upcoming events Theradiag will attend:
- January 21-24, 2020: 10th Congress of Human and Medical Genetics, Tours, France
- January 24, 2020: 13th National Conference of IBD (Chronic Inflammatory Bowel Diseases), Paris
- February 12-15, 2020: 15th ECCO (European Crohn’s and Colitis Organisation) Congress, Vienna, Austria
- March 5-6, 2020: Biomed-J 2020 (Young Medical Biologists’ Association), Paris
- March 6-7, 2020: GETAID Seminar (Therapeutic Study Group for Inflammatory Digestive Tract Diseases), Paris
- March 26-29, 2020: JFHOD congress (Hepato-gastroenterology and Digestive Oncology), Paris.
About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 60 employees.
For more information about Theradiag, please visit our website: www.theradiag.comTheradiag CEO/Managing Director Bertrand de Castelnau Tel.: +33 (0)1 64 62 10 12 | NewCap Financial Communications & Investor Relations Sandrine Boussard-Gallien Tel.: +33 (0)1 44 71 94 94 | NewCap Media Relations Nicolas Mérigeau Tel.: +33 (0)1 44 71 94 98 |